Image Source: Potato Pro

Syngenta is rapidly scaling up its portfolio of nature-inspired, science-backed biological solutions, marking a bold pivot towards sustainable agriculture and reinforcing its ambition to become the global leader in biologicals.

In a series of strategic moves, Syngenta has expanded its biologicals footprint through high-impact acquisitions, cutting-edge research, and new manufacturing capacity. The December 2024 acquisition of Intrinsyx Bio, a nutrient-use efficiency (NUE) innovator, and the early 2025 integration of Novartis’ Strains and Natural Products Collection are expected to fast-track development of next-gen biocontrols, biostimulants, and NUE products.

The company also inaugurated a 22,000 m² facility in Orangeburg, South Carolina, with an annual biostimulant production capacity of 16,000 tons, reinforcing its global manufacturing network across Brazil, Italy, India, and Norway.

Biologicals—derived from naturally occurring substances—are key to regenerative agriculture, enabling higher productivity with lower environmental impact. Syngenta’s R&D hubs in Switzerland, the UK, and Italy are driving commercialization of promising biological candidates, each with projected annual sales exceeding $100 million.

The timing is strategic: the global biologicals market, currently growing at ~10 per cent CAGR, is projected to hit $ 20 billion by 2030, according to AgbioInvestor and Syngenta estimates.

Strong Q1 2025 performance—particularly in North America and China—underscores Syngenta Biologicals’ commercial momentum as farmers worldwide seek high-performance, sustainable tools to navigate climate stress, regulatory shifts, and consumer demand for clean-label agriculture.